Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.

Leukemia - 1 Feb 2026

Santini Valeria, Zeidan Amer M, Van Eygen Koen, Fenaux Pierre, Germing Ulrich, Madanat Yazan F, Raza Azra, Savona Michael R, Sekeres Mikkael A, Thépot Sylvain, Raddi Marco G, Boyer Thomas, Sun Libo, Wan Ying, Berry Tymara, Xia Qi, Huang Fei, Dougherty Souria, Navada Shyamala, Feller Faye, Komrokji Rami S, Platzbecker Uwe

Abstract excerpt

Existing treatments for lower-risk myelodysplastic syndromes/neoplasms (LR-MDS) focus on symptom relief. Until recently, altering the disease course was rarely considered a therapeutic objective. The first-in-class, direct, competitive telomerase inhibitor, imetelstat, demonstrated significantly higher rates of red blood cell (RBC) transfusion independence (TI) versus placebo in patients with non-del(5q), RBC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Erythrocyte Transfusion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Frequency

Share to SF3B1 gene

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Oligonucleotides

Share to Telomerase

Source

Open in PubMed Open full text

Identifiers

PMID: 41526614
DOI: 10.1038/s41375-025-02831-z
PMCID: PMC12875879

Genes

ASXL1
DNMT3A
SF3B1
TET2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.PMID 41526614Read ↗

Therapy for lower-risk MDS.Semantic proximity Read ↗

Response Predictors and Clonal Evolution during Thalidomide Therapy in Myelodysplastic Neoplasms with Increased BlastsSemantic proximity Read ↗

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study.Semantic proximity Read ↗

IL-1β–mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromesSemantic proximity Read ↗

Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS.Semantic proximity Read ↗

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.Semantic proximity Read ↗

Lowering the boom on lower-risk myelodysplastic syndromes.Semantic proximity Read ↗

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.Semantic proximity Read ↗

Long-Term Clinical and Molecular Dynamics in Hypoplastic Myelodysplastic Neoplasia Treated With Immunosuppressive Therapy.Semantic proximity Read ↗

Optimizing hypomethylating agents in myelodysplastic syndromesSemantic proximity Read ↗

Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms.Semantic proximity Read ↗

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.